OTLK Long Trade Setup | Entry, SL, T1, T2!Type: Long Trade 📈
Entry Point: $2.31 (marked breakout level)
Stop Loss (SL): $2.18 (marked in red) 🚫
Target 1 (T1): $2.44 (marked in yellow) 🟡
Target 2 (T2): $2.60 (marked in green) ✅
Reason for Long: Symmetrical triangle breakout pattern with bullish momentum. The price broke through the resistanc
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.14 USD
−75.37 M USD
0.00 USD
20.52 M
About Outlook Therapeutics, Inc.
Sector
Industry
CEO
Lawrence A. Kenyon
Website
Headquarters
Iselin
Founded
2010
FIGI
BBG00469JRJ5
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
OTLK Breakout Trade Setup: Entry, Targets & Risk Friday! Stop-Loss (SL): 2.05 📉
Entry: Above 2.19 📈
Target 1 (T1): 2.34 🎯
Target 2 (T2): 2.55 🚀
Conclusion:
Break above 2.19 signals a potential trend reversal. Targets 2.34 and 2.55 offer favorable rewards. Use 2.05 as SL to manage risk.
💡 Stay disciplined!
⚠️ Risk-Reward in favor.
📈 Breakout opportunity!
Outlook Therapeutics $2.24. Huge potential upside.Outlook Therapeutics are a bio drug company specialising in treating a progressive eyesight problem that affects millions of elderly people worldwide. The disease is called wet macular degeneration.
Outlook have been given approval in Europe and the uk for their new treatment and plan to sell the tr
OTLK Surged 22% On Positive Opinion from CHMPOutlook Therapeutics, Inc. (Nasdaq: NASDAQ:OTLK ), a pioneering biopharmaceutical company, has achieved a significant milestone in the realm of ophthalmic healthcare. With the recent issuance of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine
Roadmap for OTLKBlue solid lines are established downtrends, green dotted lines are established uptrends. Both the uptrend and downtrend lines are established from equilibrium points, (not highs and lows). Thickness of lines illustrates strength of previous price action. Circles are the crossing of uptrend and down
$OTLK is gonna fall todayPupm&Dump trading strategy idea.
$OTLK is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $2,89;
stop-loss — $3,20;
take-profit — $2,27.
Do not view th
$OTLK good buy for long term investment$OTLK seems to be breaking out upside on the bullish news - reported statistically significant achievement on Phase 3 trial for both Primary and Secondary endpoints!
The chart also shows the double bottom pattern completed with parallel channel formed above it, which is now being broken out upward
OTLK Swing-trade (and potential long-term growth) ideaOTLK (Outlook Therapeutics, Inc.) is expected to commercialize the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, Greater China and other markets. The stock recently spiked up in antic
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of OTLK is 1.53 USD — it has decreased by −1.29% in the past 24 hours. Watch Outlook Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Outlook Therapeutics, Inc. stocks are traded under the ticker OTLK.
OTLK stock has risen by 11.68% compared to the previous week, the month change is a 11.68% rise, over the last year Outlook Therapeutics, Inc. has showed a −81.20% decrease.
We've gathered analysts' opinions on Outlook Therapeutics, Inc. future price: according to them, OTLK price has a max estimate of 24.00 USD and a min estimate of 3.00 USD. Watch OTLK chart and read a more detailed Outlook Therapeutics, Inc. stock forecast: see what analysts think of Outlook Therapeutics, Inc. and suggest that you do with its stocks.
OTLK reached its all-time high on Sep 1, 2016 with the price of 878.40 USD, and its all-time low was 0.87 USD and was reached on Nov 27, 2024. View more price dynamics on OTLK chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
OTLK stock is 4.64% volatile and has beta coefficient of 0.46. Track Outlook Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Outlook Therapeutics, Inc. there?
Today Outlook Therapeutics, Inc. has the market capitalization of 49.91 M, it has increased by 5.07% over the last week.
Yes, you can track Outlook Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Outlook Therapeutics, Inc. is going to release the next earnings report on May 14, 2025. Keep track of upcoming events with our Earnings Calendar.
OTLK earnings for the last quarter are −0.89 USD per share, whereas the estimation was −0.76 USD resulting in a −17.11% surprise. The estimated earnings for the next quarter are −0.54 USD per share. See more details about Outlook Therapeutics, Inc. earnings.
Outlook Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 0.00 USD. In the next quarter, revenue is expected to reach 628.25 K USD.
OTLK net income for the last quarter is 17.38 M USD, while the quarter before that showed 5.69 M USD of net income which accounts for 205.34% change. Track more Outlook Therapeutics, Inc. financial stats to get the full picture.
No, OTLK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 27, 2025, the company has 23 employees. See our rating of the largest employees — is Outlook Therapeutics, Inc. on this list?
Like other stocks, OTLK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Outlook Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Outlook Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Outlook Therapeutics, Inc. stock shows the sell signal. See more of Outlook Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.